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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of intensive glycaemic control compared to conventional control on the outcome of foot ulcers in patients with
type 1 and type 2 diabetes.
B A C K G R O U N D
Description of the condition
In 2011, 366 million people worldwide (8.3% of adults) were es-
timated to have diabetes mellitus (IDF 2012). It is expected that
this figure will reach 552 million (10% of adults) by 2030 (IDF
2012). Diabetes mellitus is a metabolic disorder characterised by
dysregulation in blood glucose levels. Type 1 diabetes (previously
known as insulin-dependent, juvenile or childhood-onset) is char-
acterized by deficient insulin production and requires daily ad-
ministration of insulin (IDF 2012). The cause of type 1 diabetes
is not known and it is not preventable with current knowledge
(IDF 2012). Type 2 diabetes (formerly known as non-insulin-de-
pendent or adult-onset) results from the body’s ineffective use of
insulin. Ninety per cent of people with diabetes, worldwide, have
type 2 diabetes (IDF 2012). One of themajor complications of di-
abetes is foot ulceration (Boulton 2004). A diabetic foot ulcer has
been defined as either a full-thickness wound below the ankle in
patients with diabetes, irrespective of duration (Apelqvist 1999),
or a lesion of the foot penetrating through the dermis (Schaper
2004). The prevalence of foot ulceration in people diagnosed with
diabetes is 4% to 10%; the annual population incidence is 1% to
4%, and the lifetime incidence is as high as 25% (Singh 2005). In
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a recent multi-centre study, poor glycaemic control (blood glucose
control) was evident in nearly half of the participants who had
foot ulcers, with 49% having an HbA1c (glycaemic measure) level
above 8.4% (Schaper 2012).
Foot ulceration is caused by the interplay of several factors, most
notably diabetic peripheral neuropathy (DPN, i.e. loss of sensation
to the foot), peripheral arterial disease (PAD, i.e. lack of blood-
flow) and changes in foot structure (Clayton 2009; Shenoy 2012).
These factors have been linked to chronic hyperglycaemia (high
levels of glucose in the blood) and the altered metabolic state of
diabetes (Ikem 2010; Ogbera 2008; Tesfaye 2012).The prevalence
of DPN ranges from 16% to 66% in people with diabetes (Cook
2012). The prevalence rates for PAD are as high as 50% in patients
with diabetic foot ulcers (Hinchliffe 2012). What is most notable,
is that within one year of an ulcer healing, up to 60% of patients
will develop another foot ulcer (Wu2007), and often the end point
is lower limb-amputation.
It is currently estimated that there is an amputation every 30 sec-
onds, somewhere in the world, that is due to diabetes (Game
2012). The estimated likelihood of amputation is 10 to 30 times
higher amongst people with diabetes compared to those without
diabetes and 85% of all amputations in people with diabetes are
preceded by a foot ulcer (Boulton 2004; Singh 2005). The five-
year mortality rate after the onset of a foot ulcer ranges from 43%
to 55%, and is up to 74% for patients with lower limb amputation
(Robbins 2008).
Description of the intervention
Chronic hyperglycaemia appears to be one of the most important
factors in the development of diabetic foot ulcers, and the poten-
tial of ulcers to heal (Christman 2011; Falanga 2005). Current
guidelines recommend that treatment should involve a multidis-
ciplinary team, as well as utilising several interventions (Table 1).
This review is performed to clarify the effect of intensive glycaemic
control on the healing of foot ulcers in people with diabetes.
The management of diabetes includes glycaemic control (Table
2) (Daroux 2010; Geraldes 2010; Giacco 2010; Inzucchi 2012).
A common list of glycaemic control medications used in diabetes
management is shown inTable 3.Most guidelines have a glycaemic
control target of 7% or lower for HbA1c (glycated haemoglobin)
(Table 2). The revised guidelines of the American Diabetes Asso-
ciation (ADA) and the European Association for the Study of Dia-
betes (EASD) recommend individualisation, with more stringent
(6.5% or lower) or less stringent (8% or lower) HbA1c targets as
appropriate for individuals (ADA 2012; Cheung 2009; Inzucchi
2012). There is a marked variation in the definition of inten-
sive glycaemic control between guidelines and trials (Hemmingsen
2011a). For the purposes of this review we will include trials where
an intervention has been performed with the aim of achieving im-
proved glycaemic control in comparison to a conventional control
group.
Most of the current glycaemic targets for diabetes are based on
several landmark trials that investigated the effects of intensive
glycaemic control compared to conventional treatments (Table 2)
(Cheung 2009; Hemmingsen 2011b; Macisaac 2011; Mazzone
2010). The findings from these studies also illustrate the benefits
and risks associated with intensive glycaemic control. Therefore,
when investigating intensive glycaemic control as a potential in-
tervention for diabetic foot ulcers, it is important to take into ac-
count the present literature underpinning current glycaemic man-
agement.
Intensive glycaemic control implemented in the Diabetes Control
and Complications Trial (DCCT) and United Kingdom Prospec-
tive Diabetes Study (UKPDS) led to a reduction in the progres-
sion and development of microvascular (small vessel) complica-
tions including DPN (Mattila 2010). The UKPDS demonstrated
a 37% reduction in the risk of microvascular complications for
each 1% decrease in HbA1c (95% confidence interval: 33% to
41%) (UKPDS 1998; Stratton 2000). Similarly, the ADVANCE
trial found a 14% relative risk reduction for major microvascu-
lar events in the intensive control group when compared to the
standard control group (9.4% versus 10.9%; hazard ratio (HR)
0.86; 95% CI: 0.77 to 0.97), although mainly in terms of reduced
incidence of nephropathy (kidney disease) (ADVANCE 2007).
A recent Cochrane review concluded that intensive glucose con-
trol reduced the risk of amputation by 36% in type 2 diabetes (rel-
ative risk (RR) 0.64, 95% CI: 0.43 to 0.95; 6960 participants in
eight trials) (Hemmingsen 2011b). In addition there was an 11%
relative risk reduction (RR 0.89, 95% CI: 0.83 to 0.95; 25,760
participants in four trials) and a 1% to 2% absolute risk reduc-
tion in composite microvascular outcomes in favour of intensive
glycaemic control for all included trials (Hemmingsen 2011b). A
number of meta-analyses have demonstrated that the incidence
of hypoglycaemia (low blood sugar) was increased during inten-
sive glycaemic control, making this a significant adverse outcome
(Hemmingsen 2011b; Ma 2009; Mattila 2010). It must be noted
that the beneficial effects on microvascular complications from
using intensive glycaemic control took more than five years to
emerge, and the benefits were less pronounced for people with
advanced type 2 diabetes compared to those with new-onset type
2 diabetes (Hemmingsen 2011b;Mattila 2010). Despite this, data
on retinopathy (disease of the retina) suggest that people with the
advanced stages of type 2 diabetes may also benefit from intensive
glycaemic control (Hemmingsen 2011a). The effects of intensive
glycaemic control in people with type 1 diabetes demonstrated in
the DCCT were still evident after 14 years of follow-up (i.e. long
after the intervention was completed), and this phenomenon has
been termed ’glycaemicmemory’ (Giacco 2010).More recent data
suggests that glycaemic memory also occurs in people with type
2 diabetes, where it is termed the ’legacy effect’, whereby benefits
of earlier interventions are evident later on in disease progression
(Giacco 2010).
While intensive therapy, with the goal of achieving near normal
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HbA1c levels (7%), has altered the clinical course of nephropathy,
neuropathy and retinopathy, the majority of studies have not ex-
amined the benefits of intensive therapy when implemented after
the onset of late diabetes complications, such as diabetic foot ul-
cers (Nathan 2012).
How the intervention might work
Hyperglycaemia has been associated with delayed healing of
foot ulcers (Burakowska 2006; Christman 2011; D’Souza 2009;
Falanga 2005; Rafehi 2010). Therefore, interventions that tar-
get improvements in glycaemic control are of potential benefit.
Delayed healing of foot ulcers appears to be the net result of
both microvascular and macrovascular disease (Burakowska 2006;
Dinh 2005). Well-orchestrated wound healing is essential for
tissue replacement and restoration, and generally involves three
main phases: acute inflammation, proliferation, and remodelling
(Rafehi 2010). In contrast, diabetic foot ulcers do not follow the
orderly process of wound healing and differ at a molecular level
in terms of expression of growth factors, cytokines and proteins
(Dinh 2005; Rafehi 2010). These processes are known to be af-
fected by hyperglycaemia.
Several proposed pathogenic pathways exist to explain the adverse
effects of hyperglycaemia (Geraldes 2010). These include: 1) ac-
tivation of the polyol pathway; 2) non-enzymatic glycosylation
and formation of advanced glycation end products (AGEs); 3)
activation of the diacylglycerol- (DAG) protein kinase C path-
way; and 4) overactivity of the hexosamine pathway (Brownlee
2004; Geraldes 2010; Giacco 2010; Gupta 2010). All four mecha-
nisms have been linked to a single, unified preceding event, namely
mitochondrial overproduction of reactive oxygen species (ROS)
(Brownlee 2004). ROS are known to promote cellular dysfunc-
tion through damage to DNA synthesis, oxidation of lipids and
amino acids and inactivation of key enzymes in metabolic func-
tion, which are implicated in the formation of diabetic foot ulcers.
Hyperglycaemia also promotes endothelial dysfunction, vascular
leakage and impaired angiogenesis (formation of new blood ves-
sels) originating from the above mentioned pathways, and leads
to activation of the inflammatory response via activation of nu-
clear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) (D’Souza 2009; Giacco 2010). The incidence of infection is
also increased in people with diabetes, and different immunologi-
cal disturbances, such as deficiencies in polymorphonuclear leuko-
cyte, monocyte and macrophage (types of white blood cell) func-
tion have been noted during hyperglycaemia (Delamaire 1997;
Stegenga 2008). All these factors, which are a consequence of
hyperglycaemia, may play a role in delayed healing of foot ulcers.
A recent observational study showed thatHbA1cwas an important
clinical predictor of the rate of wound healing; with each 1%
increase in HbA1c level associated with a decrease in the wound
healing rate of 0.028 cm² per day (95% CI: 0.003 to 0.054) (
Christman 2011). Despite this, the effects of short-term reduction
inHbA1cdidnot appear to have any effect on endothelial function
in patients with type 2 diabetes with a history of poor glycaemic
control (Bagg 2001). Therefore, there remains a clear need to
document benefits associated with improved glycaemic control
in the diabetic foot ulcer population (Idris 2005). While chronic
complications of diabetes such as DPN and PAD maybe difficult
to reverse, it can be postulated that aspects of ulcer healing relating
to immunological and connective tissue function may be more
amenable to improvement if normoglycaemia (normal level of
sugar in blood) is achieved (Jeffcoate 2004).
Why it is important to do this review
Foot ulcers continue to be a significant burden for patients with di-
abetes, their caregivers and the healthcare system (Schaper 2012).
The outcome of a foot ulcer in people with diabetes should not
only be viewed from a clinical perspective (e.g. healing and am-
putation), but also from a patient and socioeconomic perspective.
Health-related quality of life (HRQoL) is significantly reduced in
patients with diabetes, and further impaired by the presence of
foot disease, whilst it is improved with foot ulcer healing (Hogg
2012). Healthcare costs associated with foot ulcers and amputa-
tions contribute significantly to the financial burden of diabetes
(Jones 2007). In the United States in 2008, the total number of
discharges attributed to diabetes-related amputations was 45,000.
The average length of stay was 10.1 days and the in-hospital mor-
tality rate was 1.29% (Cook 2012). The mean hospital charges
were USD 56,216 per patient and the estimated aggregate cost for
the year 2008 was USD 2,548,319,965 (Cook 2012).
Therefore, foot ulceration in people with diabetes has substantial
socioeconomic, quality of life, and health care implications, and
it is imperative that all efforts be made to prevent and treat the
burden of foot ulceration in order to reduce amputation rates - as
highlighted by the St Vincent Declaration in 1989 (Game 2012).
Optimum healing of a foot ulcer requires a well-orchestrated in-
tegration of molecular and biological events including, cell mi-
gration, proliferation, extracellular matrix deposition and remod-
elling, which is hindered by the effects of hyperglycaemia (Falanga
2005; Rafehi 2010).
Advances in the treatment of diabetic foot ulcers are promising,
however the intrinsic pathophysiological abnormalities of hyper-
glycaemia that lead to ulceration and delayed ulcer healing can-
not be ignored (Falanga 2005). Recent changes to glycaemic tar-
gets and current emphasis on individualisation of glycaemic tar-
gets seems to open a new era in diabetes management. The review
authors believe that this systematic review and meta-analysis will
assess the effectiveness of intensive glycaemic control in the man-
agement of diabetic foot ulcers.
O B J E C T I V E S
3Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Protocol)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
To assess the effects of intensive glycaemic control compared to
conventional control on the outcome of foot ulcers in patients
with type 1 and type 2 diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published and unpublished randomised controlled trials (RCTs)
will be considered for inclusion where they investigate the effects
of intensive glycaemic control on the outcome of active foot ulcers
(either as a primary or secondary outcome). Non randomised and
quasi-randomised trials will be excluded.
Types of participants
Men and women (over 18 years) diagnosed with type 1 or type
2 diabetes by clearly-defined, accepted standards relevant to the
time of the study, with an active foot ulcer that has any of the
following aetiologies (causes):
• neuropathic, or
• neuro-ischaemic, or
• ischaemic, with or without
• infection (as clinically or diagnostically documented by
laboratory analysis).
For the purposes of this review, venous ulcers, malignant ulcers
and post-surgical ulcers will be excluded.
Types of interventions
Wewill include trials that have assessed any intervention that aims
to achieve a lower glycaemic target in a diabetes group (i.e. near
normal glycaemic levels) when compared to a control group with
a higher glycaemic target. The latter group is then defined as a
’conventional’ group. Therefore the intensive group will have a
lower glycaemic target level compared to the conventional group
in the trial. Trials will be included where the reported level of
glycaemia is lower in the intensive group.
Therefore, we will include any intervention that has:
1) attempted to maintain or control blood glucose levels and mea-
sured changes in markers of glycaemic control (HbA1c or fasting,
random, mean, home capillary or urine glucose), and
2) documented the effect of these interventions on active foot ulcer
outcomes.
Interventions may include more frequent subcutaneous insulin
administration, continuous insulin infusion or oral anti-diabetic
agents - or both - as well as any lifestyle interventions (Table 4).
The definition of the conventional (comparison) group is that it
should have a higher glycaemic target than the intervention group.
Pharmaceutical treatment may include any route of administra-
tion, dose, duration or frequency of insulin and/or other pharma-
ceutical agents.
Types of outcome measures
Primary outcomes
• Number of ulcers healed
• Time to complete healing.
• Change in ulcer severity reported as a change in an ulcer
grading score using a well-defined validated ulcer grading scale;
e.g. University of Texas Wound Classification System (UTWCS)
that measures the depth, presence of infection and ischaemia of
an ulcer (Armstrong 1998).
• Incidence of amputation (identified on International
Classification of Disease (ICD) codes (NCCH 2006).
Secondary outcomes
• New ulcer development (re-occurrence of an ulcer or
initiation of a new ulcer).
• Proportion of infected ulcers at study completion.
• Adverse events: adverse events will be noted from each
individual trial, and, where trial reports are based on a sound
methodology with standardised approach to detect and assess
adverse events, these will be included in any potential analysis
and judged on a case by case basis. Treatment-focused examples
include: adverse drug reaction requiring hospitalisation; weight
gain; and hypoglycaemia. Disease-focused examples include:
worsening of neuropathy (clinically or using a validated
neuropathy score); development or worsening of PAD (clinically
or by diagnostic measurement such as ankle brachial index
(ABI); gangrene; congestive heart failure; chronic kidney disease
(CKD) (stages 1-5); dialysis; retinopathy and documented
diabetic ketoacidosis (DKA); hyperosmolar nonketotic (HONK)
hyperglycaemia; and lactic acidosis).
• Effect on HRQOL: as measured by a validated quality of
life (QOL) measurement tool that is disease-specific to foot
ulcers or generic to QOL - or both.
• Cost of intervention compared to conventional treatment,
including: direct medical costs; direct non-medical costs (e.g.
transport, assistive devices); indirect costs (e.g. sick leave,
reduced productivity, early retirement and premature death);
disability-adjusted life years (DALY) and years of life lost (YLL).
• All cause mortality.
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Search methods for identification of studies
Electronic searches
Wewill search the following electronic databases to identify reports
of relevant randomised clinical trials:
• The Cochrane Wounds Group Specialised Register;
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (latest issue);
• EMBASE via Ovid (1980 to present);
• MEDLINE via Ovid (1946 to present);
• CINAHL plus via EBSCOHost (1981 to present);
• SCOPUS (1960 to present);
• Web of Science via ISI Web of Knowledge (1965 to
present);
• BioMed Central (1997 to present);
• LILACS (1995 to present).
We will searchThe Cochrane Central Register of Controlled Trials
(CENTRAL) using the following exploded MeSH headings and
keywords:
#1 MeSH descriptor: [Blood Glucose] explode all trees
#2 MeSH descriptor: [Hypoglycemic Agents] explode all trees
#3 MeSH descriptor: [Hyperglycemia] explode all trees
#4 MeSH descriptor: [Hypoglycemia] explode all trees
#5 MeSH descriptor: [Insulin] explode all trees
#6 MeSH descriptor: [Metformin] explode all trees
#7 MeSH descriptor: [Thiazolidinediones] explode all trees
#8 MeSH descriptor: [alpha-Glucosidases] explode all trees
#9 MeSH descriptor: [Glucagon-Like Peptide 1] explode all trees
#10 MeSH descriptor: [Acarbose] explode all trees
#11 (blood glucose):ti,ab,kw
#12 (((glycaemic or glycemic) next control) or “intensive glucose
control”):ti,ab,kw
#13 ((hypoglycaemi* or hypoglycemi*) next (agent* or drug*)):
ti,ab,kw
#14 (oral next (hypoglycaemi* or hypoglycemi*)):ti,ab,kw
#15 (“fasting glucose” or “glucose target”):ti,ab,kw
#16 ((anti-diabetes next medication*) or (diabetes next medica-
tion*) or insulin* or sulphonyureas or metformin or thiazolidine-
dione* or DPP-4 inhibitor* or glitinide or (glucosidase next in-
hibitor*) or biguinide or “GLP-1 agonist” or acarbose or (incretin
next enhancer*) or (incretin next mimetic*) or HbA1c):ti,ab,kw
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or
#11 or #13 or #14 or #15 or #16
#18 MeSH descriptor: [Foot Ulcer] explode all trees
#19 MeSH descriptor: [Diabetic Foot] explode all trees
#20 (diabet* near/3 ulcer*):ti,ab,kw
#21 (diabet* near/3 (foot or feet)):ti,ab,kw
#22 (diabet* near/3 wound*):ti,ab,kw
#23 (diabet* near/3 defect*):ti,ab,kw
#24 (“foot gangrene” or amputat*):ti,ab,kw
#25 #18 or #19 or #20 or #21 or #22 or #23 or #24
#26 #17 and #25
The MEDLINE search will be combined with the Cochrane
Highly Sensitive Search Strategy for identifying randomised tri-
als in MEDLINE: sensitivity- and precision-maximizing version
(2008 revision); Ovid format - which is outlined in Chapter 6
of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Lefebvre 2011). The EMBASE search will be combined
with the Ovid EMBASE filter developed by the UK Cochrane
Centre, which is also cited in the Handbook (Lefebvre 2011). The
CINAHL searches will be combined with the trial filters devel-
oped by the Scottish Intercollegiate Guidelines Network (SIGN)
(SIGN2012).Wewill not restrict studies with respect to language,
date of publication or study setting.
Searches of the Cochrane Wounds Group Specialised Register,
CENTRAL, MEDLINE, EMBASE and CINAHL will be carried
out at theCochraneWounds Group editorial base.We will modify
the original search strategy shown above to search the SCOPUS,
Biomed Central, Web of Science and LILACS databases. We will
seek additional support from an institutional librarian to conduct
these searches.
We will search the following ongoing trial databases for relevant
published, non-published, ongoing and terminated clinical trials:
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/index.html);
• ClinicalTrials.gov (http://www.clinicaltrials.gov/);
• WHO International Clinical Trials Registry Platform
(ICTRP) (http://www.who.int/ictrp/en/);
• Current Controlled Trials (http://www.controlled-
trials.com)
We will also search the pharmaceutical trials databases listed below
(known pharmaceutical companies involved inmanufacture of di-
abetes medication) for relevant published, non-published, ongo-
ing and terminated clinical trials:
• AstraZeneca Clinical Trials web site
(www.astrazenecaclinicaltrials.com);
• Eli Lilly and Company Clinical Trial Registry
(www.lillytrials.com);
• Novartis (www.novartisclinicaltrials.com/webapp/etrials/
home.do);
• Novo Nordrik (http://www.novonordisk-trials.com/
WebSite/Content/Default.aspx);
• MSD (http://www.msd-australia.com.au/research/clinical-
development/home.html);
• Servier (http://www.servier.co.uk/clinical-trials/).
We will search guidelines produce by the Joanna Briggs Institute,
theNational Institute forHealth and Care Excellence (NICE), the
National Health Service (NHS), the National Health andMedical
Research Council (NHMRC), the Scottish Intercollegiate Guide-
lines Network (SIGN), National Clearinghouse and the Interna-
tional Working Group on the Diabetic Foot for any studies or
publications of relevance that have not been identified through
5Intensive versus conventional glycaemic control for treating diabetic foot ulcers (Protocol)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
other search options.
Where translation(s) is required, we will contact the origi-
nal authors first to acquire an English-language version of the
manuscript. If the authors are not able to provide an English ver-
sion, then the articles will be translated to English using translation
services from the local hospital or through the Cochrane Wounds
Group.
Searching other resources
We will check the reference lists of all included and excluded stud-
ies for any further studies of relevance.We will also contact key lo-
cal and international pharmaceutical groups regarding any unpub-
lished trials. All international and national clinical guidelines in
themanagement of diabetic foot ulcers will be screened for any ad-
ditional studies. We will also contact leading academics,clinicians
and researchers in the area of diabetes management and man-
agement of diabetic complications, for information about any
prospective or past studies not identified by the literature searches.
Data collection and analysis
Selection of studies
Two review authors (MF and RS) will retrieve and assess articles
for inclusion independently using these selection criteria; the title,
abstract or key-words - or both - of a potentially-relevant study to
assess whether the study investigated:
1) changes in glycaemic state of participants with type 1 or type
2 diabetes via changes in markers of glycaemic control (HbA1c or
fasting, random, mean, home capillary or urine glucose), and
2) foot ulcer outcomes.
Full text publications of all articles meeting these selection criteria
will be assessed. Any articles that are deemed not to be suitable
will be excluded (exclusion after screening of full-text). Differences
in opinion regarding whether to include or exclude a study will
be resolved by three third parties (JG, KS, YT). If no resolution
is achieved, or possible, the original authors of the study will be
contacted for further clarification, so that we know whether to
include the study, or not. The selection process will be plotted
as a PRISMA flow diagram (Moher 2009). All citations will be
managed using Endnote version 5.1 (Thomson Reuters 2012). A
table demonstrating the reasons for exclusion for all excluded trials
will be constructed.
Data extraction and management
Data extraction will be conducted independently by two review
authors (MF and RS) and entered into a structured electronic data
format using theCochraneWounds Group extraction form to col-
lect and organise data.This will include information concerning:
• general information about the study (i.e. location, setting,
aims);
• study eligibility;
• characteristics of study methods;
• participants;
• intervention groups;
• outcomes;
• ’Risk of bias’ assessment;
• areas for sub-group analysis areas.
The data will include information on participant characteristics,
study design, interventions utilised, outcomes assessed, and ad-
verse events.
Disagreements between the two review authors will be resolved by
a third (MC) and fourth review author (PB).
Meta-analysis will be conducted on reported outcomes only (i.e.
where outcome data on ulcer reduction are provided, but not on
amputation; meta-analysis can be done for ulcer reduction but
not for amputation). All studies meeting inclusion criteria and
reporting outcome variables of interest will be included in the
review; where possible, all studies meeting eligibility for meta-
analysis will be included in meta-analysis.
Dealing with duplicate publications
When more than one publication is found for a study, we will
evaluate all publications together to extract the maximum amount
of relevant information. Any discrepancies between the studies will
be resolved by contacting the study authors. If there are repeated
observations of the same participants, the longest follow-up period
will be used for defining outcome measures of this study.
Assessment of risk of bias in included studies
The risk of bias will be assessed using the guidelines provided in
the Cochrane Handbook of Systematic Reviews of Interventions
(Higgins 2011a). Risk of bias will be rated as low, high or unclear
in nature (Higgins 2011b), and a ’Risk of bias’ graph and ’Risk of
bias’ summary will be included. Two review authors (MF and RS)
will assess each study independently.
We will use the following bias criteria:
• sequence generation (selection bias);
• allocation concealment (selection bias): a summary of how
allocation sequences were generated and attempts to conceal
allocation of assigned intervention will be reported, along with
any judgements concerning the risk of bias that may arise from
the methods used;
• blinding for participants, personnel and outcome
assessment (performance and detection bias): a brief summary of
who was blinded or masked during the conduct and analysis of
the studies will be reported. Implications regarding blinding of
outcome assessment may vary for different outcomes, so these
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may need to be addressed separately. Judgements concerning the
risk of bias associated with blinding will be summarised;
• incomplete outcome data (attrition bias): review authors’
concerns over exclusion of participants and excessive (or
differential) drop-out rates will be reported;
• selective reporting (reporting bias): concerns over the
selective availability of data may be summarised, including
evidence of selective reporting of outcomes, time-points,
subgroups or analyses;
• other bias(es) identified.
We will present our assessments using a ’Risk of bias’ summary
figure, which will present all bias assessment points in a table
format.
Measures of treatment effect
For dichotomous data, we will present results as summary risk
ratios with 95% confidence intervals. For continuous data, when
outcomes were measured the same way between trials, we will use
the mean difference. We will use the standardised mean difference
to combine trials that measured the same outcome, but used dif-
ferentmethods of measurement. Time to complete wound healing
is time-to-event data; the most appropriate way of summarising it
is to use methods of survival analysis and to express the interven-
tion effect as a hazard ratio. It is not appropriate to analyse time-
to-event data using methods used for continuous outcomes (e.g.
using mean times-to-event), as the relevant times are only known
for the subset of participants who have had the event. Censored
participants must be excluded, which, almost certainly, will intro-
duce bias. Time-to-event data that were presented incorrectly as
continuous data will not be analysed, but will be presented in a
narrative format in the review (Higgins 2011a).
Unit of analysis issues
The unit of analysis used in each individual study will be identified
in relation to a wound, a foot, a participant or as multiple wounds
on the same participant. Where studies have incorrectly treated
multiple wounds on a participant as being independent, rather
thanusingwithin-patient analysismethods, thiswill be recorded in
the ’Risk of bias’ assessment. For wound healing and amputation,
unless otherwise stated, where the number of wounds appears to
equal the number of participants, the wound will be treated as the
unit of analysis. We will treat these studies with caution; we will
include them in the systematic review, but conduct any potential
meta-analysis with, and without, them in sensitivity analyses, to
assess the effect they have on the results. The level of randomisa-
tion of each trial will also be assessed; the number of observations
should match the number of units randomised. Where the unit
of analysis is unclear, the trial author will be contacted for results
per person.
For adverse event data, the unit of analysis will be assessed on a trial
by trial basis to establish whether the data were at participant level,
or whether multiple events per participant were possible. Where
the latter is the case, although the data can be reported on a trial
by trial basis, they cannot be analysed further without violating
assumptions of independence. The method of data collection, and
potential risks of measurement and performance biases, as well as
the unit of analysis of adverse event data will be discussed in detail
in the review.
If multiple treatment arms are reported, we will carry out multiple
meta analyses using one treatment arm respectively. If more than
one control group is used or where a single ’conventional’ control
group is not recognisable, wewill combine all control group results
and carry out a pooled analyses of all control groups against the
intervention group.
In relation to the inclusion of cluster RCTs, we will attempt anal-
ysis where relevant information is available (i.e. the number, or
mean size, of clusters, outcome data for total individuals with
events, and an estimate of the intra-cluster/intra-class correlation
coefficient (ICC). A more reliable analysis will then be conducted
by reducing the size of each trial to its effective sample size us-
ing the design effect of a cluster RCT, and the standard error
will be obtained from confidence intervals, as recommended by
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a). Then any potential meta-analysis can be per-
formed using the inflated variances.
Dealing with missing data
Missing information will be sought from the original authors by
emailing the contact person for the published studies. In partic-
ular, where the reported findings of a study extend beyond foot
ulcers and it is difficult to determine the data relating to foot ul-
cers, the authors will be contacted for the relevant data. When
responses are not received, we will contact additional authors from
the publication. To avoid overly positive answers and the risk of
false information, open-ended questions will be used for contact-
ing authors (Higgins 2011a). If information relating to outcomes
(according to outcome measures) is missing, then the article will
not be included in this review.
Therefore, multiple efforts will be made to acquire any missing
data from authors. We will inspect factors such as attrition rates,
drop-out rates, randomised and included subject numbers, as well
as numbers for intention to treat, treated per protocol and losses
to follow-up carefully. These will be appraised critically and their
impact on the data will be assessed in the light of the results of the
review.
Sometimes measures of dispersion are not recorded. Where the
standard error (SE) or the t-statistic is reported, standard deviations
will be calculated with statistical assistance from PB. If the authors
did not report the aetiology of ulcers, they will be contacted for
details. If the authors are unable to confirm aetiology, the study
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will be excluded.
Assessment of heterogeneity
Clinical heterogeneity
We will determine potential reasons for heterogeneity by explor-
ing individual study and sub-group characteristics such as age and
gender of participants, risk factors for foot ulceration, duration of
disease, initial size of ulcer, type of treatment, duration of follow-
up, presence or absence of infection, history of ulceration, history
of significant cardiovascular events, presence or absence of PAD,
type of ulcer, location of ulcer, time to ulcer healing, type of med-
ication used, as well as how ulcer healing was defined within the
context of the study.
Methodological heterogeneity
The formal assessment of bias of each study, as described above,
will help identify methodological heterogeneity between studies.
Statistical heterogeneity
Forest plots, Q and I2 statistics will be used to indicate heterogene-
ity. If heterogeneity is present, then we aim to identify the studies
that produce it, and to conduct an analysis without them. With
the I2 statistic, values of 75% or more will be taken as indicative
of high levels of heterogeneity (Higgins 2011a), and will be used
to assess further the heterogeneity of studies.
Only those studies that are clinically, methodologically and sta-
tistically homogenous will be pooled for meta-analysis effect-size
calculations. Sub-group analysis will be defined by the factors
we identify as being responsible for heterogeneity, as mentioned
above.
Assessment of reporting biases
Funnel plots will be used to assess publication bias, if there are a
sufficient number of studies (10 or more) available. If there are not
enough studies in the meta-analysis for constructing a meaningful
funnel plot, then the potential for publication bias will only be
discussed.
Data synthesis
Wehave consulted theCochrane Collaboration recommendations
and decided to conduct both random-effects and fixed-effectmod-
els where appropriate for any potential meta-analysis. For example
where clinical, methodological and statistical heterogeneity are not
apparent, similar studies will be pooled in a fixed-effect model.
Where any of the above mentioned heterogeneity is evident, or
whereby I2 valueswhich demonstrate heterogeneity are significant,
a random-effect model will be utilised. Where heterogeneity levels
are insignificant and no other forms of heterogeneity are evident,
both random effect and fixed effect models will be used for com-
parison. We will attempt to investigate any significant differences
in results and heterogeneity of studies through use of these two
statistical models. If there are any vast differences between the two
methods, we will explore these differences. If fixed-effect and ran-
dom-effects meta-analyses give identical results, then it is unlikely
that there is important statistical heterogeneity, and we believe ei-
ther method will be appropriate for reporting. All studies meeting
inclusion criteria and reporting outcome variables of interest will
be included in the review. All studies meeting eligibility for meta-
analysis will be included in a meta-analysis. Meta-analysis will be
conducted separately on provided and published data, and also
on results from intention-to-treat trials. We will use Review Man-
ager for data analysis. ’Summary of findings’ tables will be used
to report each of the primary outcome variables with comparative
risk ratios (RR) and relative effects with 95% confidence intervals,
number of participants and the GRADE score along with a com-
ment about each different outcome. As mentioned previously, if
quantitative synthesis is not appropriate, findings from individual
studies will be included and discussed in the review.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be attempted at several levels in the meta-
analysis. The sub-groups will be decided after consideration of a
number of factors, and will be based on:
1. follow-up time: studies will be stratified as short-, medium-
and long-term, where less than one year of follow-up will be
considered as short-term, one to three years will be considered as
medium-term, and more than three years will be considered to
be long-term;
2. variation in the intervention and control group (e.g. groups
who received lifestyle interventions versus anti-diabetic
medication versus insulin).
Sensitivity analysis
Sensitivity analysis will be done by excluding and including studies
that cause heterogeneity in the data. Sensitivity analysis will also
be conducted by excluding and including studies that are deemed
to be of lower quality (high risk of bias). The results of sensitivity
analyses will be discussed.
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A D D I T I O N A L T A B L E S
Table 1. Diabetic foot management guidelines and levels of evidence
Guideline and management recommen-
dations
Level of evidence
(According to Oxford Centre for Evi-
dence-based Medicine - Levels of Evi-
dence (March 2009))
Glycaemic target
National Health and Medical Research
Council (NHMRC): Prevention, iden-
tification and management of foot com-
Expert opinion
Grade B
Not reported
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Table 1. Diabetic foot management guidelines and levels of evidence (Continued)
plications in diabetes mellitus 2011
• Local sharp debridement
• Topical hydrogel dressings
• Pressure reduction
• Offloading
• Removable offloading
• Multidisciplinary care management
• Negative pressure therapy
• Hyperbaric oxygen
• Larval therapy
• Cultured skin equivalents
• Skin grafting
Note: as per NHMRC levels of evidence
Grade B
Grade B
Expert opinion
Grade C
Grade B
Grade B
Grade C
Grade B
Grade D
National Clearinghouse Guidelines
2011
• Debridement with multidisciplinary
team
• Off-loading of foot ulcers
• Pressure relieving support surfaces
• Negative pressure wound therapy
• Avoid the use of:
◦ dermal or skin substitutes
◦ electrical stimulation therapy
◦ autologous platelet-rich plasma
gel
◦ regenerative wound matrices
and dalteparin
◦ growth factors
◦ hyperbaric oxygen therapy
Not reported HbA1c < 7%
Level B
National Clearinghouse guidelines 2012
(treatment of neuropathic wounds)
Assessment by a wound expert Grade C
National Health Service (NHS): Type 2
diabetes: prevention andmanagement of
foot problems 2004
• Urgent attention within 24 hours
• Multidisciplinary treatment
• Multidisciplinary team comprising
of a podiatrist, orthotists, specialised
nurse, diabetologist; with unhindered
access to suites for managing major
wounds, antibiotic administration, urgent
inpatient facilities, community nursing,
microbiology and diabetic services
• Prompt Revascularisation
• Intensive systemic antibiotic therapy
Grade D
Grade D
Grade D
Grade D
Grade C
Grade D
Grade D
Grade B
Grade B
Grade D
Grade B
Not reported
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Table 1. Diabetic foot management guidelines and levels of evidence (Continued)
• Appropriate wound dressing
• Close monitoring and regular wound
dressing changes
• Debridement of dead tissue
• Total contact casting
• Hyperbaric oxygen, cultured human
dermis, topical ketanserin or growth
factors
• Foot care reminders
National Health Service (NHS): 2011
National Institute for Health and Care
Excellence (NICE) clinical guideline.
Developed by the Centre for Clinical
Practice at NICE: Diabetic foot prob-
lems: inpatient management of diabetic
foot problems
• Debridement
• Wound dressings
• Offloading
• Antibiotics for infection
• Timing for surgical management.
Not reported Not reported
2012 International Working Group on
Diabetic Foot (IWGDF): Global guide-
line for type 2 diabetes
• Local wound care
• Relief of pressure
• Treatment of infection
• Metabolic control
• Restoration of skin perfusion
Not reported < 8 mmol/l
AustralianDiabetes FootNetwork:Man-
agement of diabetes related foot ulcera-
tion - a clinical update
• Debridement
• Dressing selection
• Pressure offloading
• Management of infection
• Glycaemic control
• Multidisciplinary care
Not reported Not reported
American College of Foot and Ankle sur-
geons 2006 (revision): Diabetic foot dis-
orders - a clinical practice guideline
• Debridement
• Pressure offloading
• Treatment of infection
• Optimise metabolic perturbations
Not reported Not reported
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Table 1. Diabetic foot management guidelines and levels of evidence (Continued)
Scottish Intercollegiate Guidelines Net-
work (SIGN) Guidelines 2010
• Referral to a multidisciplinary care
team
• Total contact casts for unilateral
ulcers
• Irremovable walkers
• Negative pressure wound therapy
• Arterial reconstruction for those who
require it
Grade C
Grade B
Grade B
Grade B
Grade B
Not reported
American Diabetes Association Stan-
dards of Medical Care in Diabetes 2012
Multidisciplinary approach
Foot ulcers and wound care may require
care by a podiatrist, orthopedic or vascular
surgeon, or rehabilitation specialist expe-
rienced in the management of individuals
with diabetes
Grade B
Not reported
As per position Statement for optimal Con-
trol
Table 2. HbA1c targets recommended by different international guidelines ª
Country Guideline Year Hba1c targets in adults Level of Evidence
(According to Oxford Cen-
tre for Evidence-
based Medicine - Levels of
Evidence (March 2009))
Australia National
Health and Medical Re-
search Council/Diabetes
Australia
2009 ≤ 7% Grade A
Australian Paediatric En-
docrine Group/ Aus-
tralian Diabetes Society
2011 ≤ 7% Grade D
UK National Institute for
Health and Care Excel-
lence (NICE)
- Managing type 1 DM
diabetes in adults
- Blood glucose lowering
therapy for type 2 DM
2012
2012
≤ 7.5% if increased arterial
risk
≤ 6.5% Between 6.5% and
7.5%
Grade B
Not reported
Not reported
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Table 2. HbA1c targets recommended by different international guidelines ª (Continued)
Scottish Intercol-
legiate Guidelines Net-
work (SIGN)
- Type 1 Diabetes
- Type 2 Diabetes
2010
No set figure
< 7%
Not reported
Grade A
USA National Clearinghouse 2012 <7%or individualize to a goal
of < 8%
Grade B
American Diabetes As-
sociation
2012 ≤ 7% or individualise to a
goal:
< 6.5%
< 8%
Grade B
Grade C
Grade B
American Association
of Clinical Endocrinolo-
gists
2011 ≤ 6.5% Grade D
International Diabetes
Federation (IDF)
International Dia-
betes Federation- Global
Guideline for type 2 Di-
abetes
2012 < 7.0% U/K
Canada Canadian Diabetes As-
sociation
2008 ≤ 7%
≤ 6.5% (may be considered
to lower risk of nephropathy
further)
Grade C, Level 3
Grade A, Level 1A
Europe European
Association for the Study
of Diabetes (EASD) and
American Diabetes As-
sociation (ADA)
2012 < 7%or individualise to a goal
of:
6-6.5% (patients with
short disease, duration, long
life expectancy, no significant
CVD)
7.5-8.0% (history of severe
hypoglycaemia, limited life
expectancy, advanced compli-
cations, extensive comorbid
conditions and those in
whom the target is difficult to
attain)
Not reported
New Zealand New Zealand Group
Guidelines
2003 ≤ 7% Grade D
ª Adapted from Australian Electronic Therapeutic Guidelines (Electronic Therapeutic Guidelines Australia 2012)
Abbreviations
CVD = cerebrovascular disease
DM = diabetes mellitus
U/K = unknown
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Table 3. Commonly used medications in diabetes mellitus (type 1 and type 2) for the management of hyperglycaemia.
Class/Drug Expected decrease in HbA1c
ORAL ANTIDIABETIC THERAPY
Metformin 1-2%
Sulfonylureas
1. glibenclamide
2. gliclazide
3. glimepiride
4. glipizide
1-2%
DPP-4-inhibitors
1. sitagliptin
2. vildagliptin,
3. axagliptin
4. linagliptin
0.5-0.8%
Acarbose 0.5-0.8%
Thiazolidinedione (glitazones)
1. pioglitazone
2. rosglitazone
0.5-1.4%
PARENTERAL THERAPY
GLP-analogues
exenatide
liraglutide
lixisenatide
0.5-1.0%
Insulin 1.5-3.5%
Insulin Generic name
Very-short-acting (rapid) Aspart
Glulisine
Lispro
Short-acting Neutral
Intermediate-acting Isophane (protamine suspension)
Long-acting Determir
Glargine
Biphasic Neutral/isophane
Lispro/lispro protamine
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Table 3. Commonly used medications in diabetes mellitus (type 1 and type 2) for the management of hyperglycaemia.
(Continued)
Aspart/aspart protamine
Methods of insulin delivery
1. Syringe
2. Pen injector
3. Pump/continuous subcutaneous insulin infusion
Table 4. Alternative treatments for lowering blood glucose in people with diabetic foot ulcers
Nature of intervention
Exercise Psychological and behavioural Dietary
Any exercise intervention that has the pri-
mary aim of improving glycaemic control
in people with diabetes, where the impact
of the intervention on glycaemic control
and changes in an active foot ulcer has been
documented
Any psychological or behavioural interven-
tion that has the primary aim of improving
glycaemic control in people with diabetes,
where the impact of the intervention on
glycaemic control and the resultant changes
in a foot ulcer has been documented
Any dietary or nutritional intervention that
has the primary aim of improving gly-
caemic control in people with diabetes,
where the changes in glycaemic control
have been correlated with changes in active
foot ulcer outcome
Examples
Exercise programs of any intensity and du-
ration that had the primary aimof improve-
ment in glycaemic control
Frequent checking of blood glucose levels,
interventions aimed at good pharmaceu-
tical practice (i.e. improving compliance
with medication)
Healthy eating programs, dietary or nutri-
tional supplements
A P P E N D I C E S
Appendix 1. Glossary of Terms
Diabetes: a disease caused by reduced production of the hormone insulin, or a reduced response of the liver, muscle, and fat cells to
insulin. This affects the body’s ability to use and regulate sugars effectively.
Diabetic Peripheral Neuropathy (DPN): damage to the peripheral nerves that is characterised by numbness, tingling, pain, or
sometimes muscle weakness, particularly in the extremities.
Peripheral Arterial Disease (PAD): narrowing or obstruction of the arteries supplying the legs that is characterised by intermittent
claudication (numbness, tingling and pain in the legs that occurs on walking, but is relieved by a short rest)
Hyperglycaemia: excessive glucose (sugar) in the blood.
HbA1c (glycated haemoglobin): a commonly used laboratory measurement that measures average blood glucose levels over the
previous two to three months.
Microvascular: small blood vessels.
Macrovascular: large blood vessel.
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Nephropathy: disorder of the kidney that includes inflammatory, degenerative and sclerotic (scar forming) conditions.
Retinopathy: disease of the small retinal blood vessels in the eye.
Growth factors: chemical messengers that induce cell growth.
Glycation: binding of a sugar molecule to an amino-acid. In hyperglycaemia, sugar molecules become attached to cell surface proteins
throughout the body; this sugar coating leads to small blood vessel damage in nerves, kidney, and the retina.
Polyol pathway: metabolic pathway involved in breakdown of excess glucose.
Advanced Glycation End products (AGEs): proteins that have been non-enzymatically modified by the addition of sugar residues.
Reactive Oxygen Species (ROS):molecules and ions of oxygen that have an unpaired electron, which makes them extremely reactive.
Many cellular structures are susceptible to damage by reactive oxygen species.
DAG-protein kinase C pathway: metabolic pathway involved in diabetes-related complications.
Hexosamine pathway: metabolic pathway involved in diabetes-related complications.
Mitochondria: involved in respiration and adenosine tri-phosphate (ATP; energy) production.
Endothelial: cells lining the heart, blood vessels and lymph vessels.
Angiogenesis: process of forming new blood vessels.
NF-κB: transcription factor involved in activation of genes involved in the inflammatory response.
Ulcer grading scale: an ulcer grading system implies any system where the dimensional change in an ulcer has been documented - e.g.
the University of Texas Wound Classification System (UTWS), PEDIS system or another.
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